591 related articles for article (PubMed ID: 18056795)
21. Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H- pyrazol-5-yl)benzamides that potentiate receptor function in vivo.
Lindsley CW; Wisnoski DD; Leister WH; O'brien JA; Lemaire W; Williams DL; Burno M; Sur C; Kinney GG; Pettibone DJ; Tiller PR; Smith S; Duggan ME; Hartman GD; Conn PJ; Huff JR
J Med Chem; 2004 Nov; 47(24):5825-8. PubMed ID: 15537338
[TBL] [Abstract][Full Text] [Related]
22. Transposition of three amino acids transforms the human metabotropic glutamate receptor (mGluR)-3-positive allosteric modulation site to mGluR2, and additional characterization of the mGluR2-positive allosteric modulation site.
Rowe BA; Schaffhauser H; Morales S; Lubbers LS; Bonnefous C; Kamenecka TM; McQuiston J; Daggett LP
J Pharmacol Exp Ther; 2008 Jul; 326(1):240-51. PubMed ID: 18430863
[TBL] [Abstract][Full Text] [Related]
23. Discovery of a Novel Chemical Class of mGlu(5) Allosteric Ligands with Distinct Modes of Pharmacology.
Hammond AS; Rodriguez AL; Townsend SD; Niswender CM; Gregory KJ; Lindsley CW; Conn PJ
ACS Chem Neurosci; 2010 Oct; 1(10):702-716. PubMed ID: 20981342
[TBL] [Abstract][Full Text] [Related]
24. In vitro pharmacological characterization of novel isoxazolopyridone derivatives as allosteric metabotropic glutamate receptor 7 antagonists.
Suzuki G; Tsukamoto N; Fushiki H; Kawagishi A; Nakamura M; Kurihara H; Mitsuya M; Ohkubo M; Ohta H
J Pharmacol Exp Ther; 2007 Oct; 323(1):147-56. PubMed ID: 17609420
[TBL] [Abstract][Full Text] [Related]
25. Unique antipsychotic activities of the selective metabotropic glutamate receptor 1 allosteric antagonist 2-cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one.
Satow A; Suzuki G; Maehara S; Hikichi H; Murai T; Murai T; Kawagoe-Takaki H; Hata M; Ito S; Ozaki S; Kawamoto H; Ohta H
J Pharmacol Exp Ther; 2009 Jul; 330(1):179-90. PubMed ID: 19359526
[TBL] [Abstract][Full Text] [Related]
26. Determination of key amino acids implicated in the actions of allosteric modulation by 3,3'-difluorobenzaldazine on rat mGlu5 receptors.
Mühlemann A; Ward NA; Kratochwil N; Diener C; Fischer C; Stucki A; Jaeschke G; Malherbe P; Porter RH
Eur J Pharmacol; 2006 Jan; 529(1-3):95-104. PubMed ID: 16352303
[TBL] [Abstract][Full Text] [Related]
27. Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus.
Uslaner JM; Parmentier-Batteur S; Flick RB; Surles NO; Lam JS; McNaughton CH; Jacobson MA; Hutson PH
Neuropharmacology; 2009; 57(5-6):531-8. PubMed ID: 19627999
[TBL] [Abstract][Full Text] [Related]
28. Effects of positive allosteric modulators on single-cell oscillatory Ca2+ signaling initiated by the type 5 metabotropic glutamate receptor.
Bradley SJ; Watson JM; Challiss RA
Mol Pharmacol; 2009 Dec; 76(6):1302-13. PubMed ID: 19737913
[TBL] [Abstract][Full Text] [Related]
29. Mutational analysis and molecular modeling of the binding pocket of the metabotropic glutamate 5 receptor negative modulator 2-methyl-6-(phenylethynyl)-pyridine.
Malherbe P; Kratochwil N; Zenner MT; Piussi J; Diener C; Kratzeisen C; Fischer C; Porter RH
Mol Pharmacol; 2003 Oct; 64(4):823-32. PubMed ID: 14500738
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological characterization and modeling of the binding sites of novel 1,3-bis(pyridinylethynyl)benzenes as metabotropic glutamate receptor 5-selective negative allosteric modulators.
Mølck C; Harpsøe K; Gloriam DE; Clausen RP; Madsen U; Pedersen LØ; Jimenez HN; Nielsen SM; Mathiesen JM; Bräuner-Osborne H
Mol Pharmacol; 2012 Nov; 82(5):929-37. PubMed ID: 22899869
[TBL] [Abstract][Full Text] [Related]
31. In vitro characterisation of the novel positive allosteric modulators of the mGlu₅ receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat.
Gilmour G; Broad LM; Wafford KA; Britton T; Colvin EM; Fivush A; Gastambide F; Getman B; Heinz BA; McCarthy AP; Prieto L; Shanks E; Smith JW; Taboada L; Edgar DM; Tricklebank MD
Neuropharmacology; 2013 Jan; 64():224-39. PubMed ID: 22884720
[TBL] [Abstract][Full Text] [Related]
32. Synergism of virtual screening and medicinal chemistry: identification and optimization of allosteric antagonists of metabotropic glutamate receptor 1.
Noeske T; Trifanova D; Kauss V; Renner S; Parsons CG; Schneider G; Weil T
Bioorg Med Chem; 2009 Aug; 17(15):5708-15. PubMed ID: 19574055
[TBL] [Abstract][Full Text] [Related]
33. Radioligand binding properties and pharmacological characterization of 6-amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-a]benzimidazole-2-carboxamide (YM-298198), a high-affinity, selective, and noncompetitive antagonist of metabotropic glutamate receptor type 1.
Kohara A; Toya T; Tamura S; Watabiki T; Nagakura Y; Shitaka Y; Hayashibe S; Kawabata S; Okada M
J Pharmacol Exp Ther; 2005 Oct; 315(1):163-9. PubMed ID: 15976016
[TBL] [Abstract][Full Text] [Related]
34. CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding.
Litschig S; Gasparini F; Rueegg D; Stoehr N; Flor PJ; Vranesic I; Prézeau L; Pin JP; Thomsen C; Kuhn R
Mol Pharmacol; 1999 Mar; 55(3):453-61. PubMed ID: 10051528
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological characterization of JNJ-40068782, a new potent, selective, and systemically active positive allosteric modulator of the mGlu2 receptor and its radioligand [3H]JNJ-40068782.
Lavreysen H; Langlois X; Ahnaou A; Drinkenburg W; te Riele P; Biesmans I; Van der Linden I; Peeters L; Megens A; Wintmolders C; Cid JM; Trabanco AA; Andrés JI; Dautzenberg FM; Lütjens R; Macdonald G; Atack JR
J Pharmacol Exp Ther; 2013 Sep; 346(3):514-27. PubMed ID: 23766542
[TBL] [Abstract][Full Text] [Related]
36. Cyclothiazide selectively inhibits mGluR1 receptors interacting with a common allosteric site for non-competitive antagonists.
Surin A; Pshenichkin S; Grajkowska E; Surina E; Wroblewski JT
Neuropharmacology; 2007 Mar; 52(3):744-54. PubMed ID: 17095021
[TBL] [Abstract][Full Text] [Related]
37. Metabotropic glutamate receptor 1 activity generates persistent, N-methyl-D-aspartate receptor-dependent depression of hippocampal pyramidal cell excitability.
Clement JP; Randall AD; Brown JT
Eur J Neurosci; 2009 Jun; 29(12):2347-62. PubMed ID: 19490024
[TBL] [Abstract][Full Text] [Related]
38. Positive and negative modulation of group I metabotropic glutamate receptors.
Vanejevs M; Jatzke C; Renner S; Müller S; Hechenberger M; Bauer T; Klochkova A; Pyatkin I; Kazyulkin D; Aksenova E; Shulepin S; Timonina O; Haasis A; Gutcaits A; Parsons CG; Kauss V; Weil T
J Med Chem; 2008 Feb; 51(3):634-47. PubMed ID: 18173231
[TBL] [Abstract][Full Text] [Related]
39. Both mGluR1 and mGluR5 mediate Ca2+ release and inward currents in hippocampal CA1 pyramidal neurons.
Rae MG; Irving AJ
Neuropharmacology; 2004 Jun; 46(8):1057-69. PubMed ID: 15111012
[TBL] [Abstract][Full Text] [Related]
40. Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity.
Rodriguez AL; Grier MD; Jones CK; Herman EJ; Kane AS; Smith RL; Williams R; Zhou Y; Marlo JE; Days EL; Blatt TN; Jadhav S; Menon UN; Vinson PN; Rook JM; Stauffer SR; Niswender CM; Lindsley CW; Weaver CD; Conn PJ
Mol Pharmacol; 2010 Dec; 78(6):1105-23. PubMed ID: 20923853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
